ASX Share rice
Sat 15 Aug 2020 - 03:13:am (Sydney)

MXC Share Price

MGC PHARMACEUTICALS LTDMXCPharmaceuticals, Biotechnology & Life Sciences

MXC Company Information

Name:

MGC Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

1202 Hay Street West Perth Australia 6005

Phone:

61 8 6382 3390

Exec. Chairman:

Mr. Brett Anthony Mitchell

Co-Founder, CEO, MD & Exec. Director:

Mr. Roby Reuven Zomer

Founder & Director:

Mr. Nativ Segev

Company Sec.:

Ms. Rachel Jelleff Kerr

Chief Exec. Officer of MGC Derma:

Hugh Winters

Company Overview:

MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and supplies phytocannabinoid derived medicines in Australia, Slovenia, and other European countries. The company provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; CannEpil and CannEKids for refractory epilepsy; and TopiCann for anti-inflammatory topical treatment. It also offers MGC CBD for anti-inflammatory, antioxidant, neuroprotector, anxiolytic, analgesic, antidepressant, anti-psychotic, and anti-tumoral agent; and MGC THC for nausea and vomiting associated with cancer medicines, as well as enhance the appetite of people with AIDS. MGC Pharmaceuticals Limited has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, The Hebrew University of Jerusalem, University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

MXC Share Price Information

Shares Issued:

1.63B

Market Capitalisation:

$40.79M

Revenue (TTM):

$2.15M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.002

Operating Margin (TTM):

$-5.59

Return On Assets (TTM):

$-0.60

Return On Equity (TTM):

$-0.90

Quarterly Revenue Growth (YOY):

5.21

Gross Profit(TTM):

$299.60K

Diluted Earnings Per Share (TTM):

$-0.007

MXC CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-947,035

Change To Liabilities:

$633.13K

Total Cashflow From Investing Activities:

$-947,035

Net Income:

$-2,309,332

Total Cash From Operating Activities:

$-6,354,210

Depreciation:

$259.74K

Other Cashflow From Investing Activities:

$-569,992

Change To Inventory:

$573.52K

Change To Account Receivables:

$-294,966

Sale Purchase Of Stock:

$-8,948

Capital Expenditures:

$362.15K

MXC Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-1,876,357

Net Income:

$-2,309,332

Gross Profit:

$299.60K

Operating Income:

$-9,039,156

Other Operating Expenses:

$415.78K

Interest Expense:

$8K

Income Tax Expense:

$27.32K

Total Revenue:

$656.24K

Total Operating Expenses:

$9.34M

Cost Of Revenue:

$356.64K

MXC Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$5.03M

Total Liabilities:

$2.20M

Total Stockholder Equity:

$10.96M

Other Current Liabilities:

$683.54K

Total Assets:

$13M

Common Stock:

$49.13M

Retained Earnings:

$-41,464,829

Other Liabilities:

$17.20K

Cash:

$2.35M

Total Current Liabilities:

$2.18M

Property - Plant & Equipment:

$1.47M

Net Tangible Assets:

$5.93M

Long-Term Investments:

$2.77M

Total Current Assets:

$3.72M

Net Receivables:

$271.02K

Short-Term Investments:

$9.28M

Inventory:

$138.80K

Accounts Payable:

$1.16M

Non Currrent Assets (Other):

$2.77M

Short-Term Investments:

$9.28

Non Current Liabilities Total:

$17.20K

MXC Share Price History

MXC News

19 Jun, 2020
Under the terms of this agreement, MGC Pharma will provide a comprehensive suite of pharmaceutical services to advance Allied’s pharmaceutical products into human clinical PHASE 1. The scope of MGC Pharma’s services will cover clinical research, IMP registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an Investigational Medicinal Product (IMP) number that is needed in order to sell the pharmaceutical product. Allied has also conducted an extensive prior art review on its previously submitted provisional patents for products AC001 and AC002 and has decided to abandon these.
15 Jun, 2020
TORONTO and GLIL YAM, Israel , June 15, 2020 /CNW/ - IM Cannabis Corp. (the "Company" or "IMC") (IMCC.CN), one of the world's pioneering medical cannabis companies with operations in Israel and across Europe , today announced that the Company has signed a binding term sheet for the exclusive distribution rights of CannEpil® in Israel for a period of five years (the "Term Sheet"). The Term Sheet follows the announcement by MGC on May 26, 2020 that the Ethics Committee of Schneider Children's Medical Center of Israel has given its approval to commence a Phase IIb clinical trial of CannEpil® in Israel .
27 May, 2020
In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize cannabis based pharmaceutical products.
15 Jan, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
10 Dec, 2019
MGC Pharmaceuticals Limited's (ASX:MXC): MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and...